Stay updated on ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial

Sign up to get notified when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the study record remains unavailable behind a 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-11-01T04:11:26.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    A sitewide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T05:00:40.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-18T04:45:51.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The site footer’s revision identifier changed from v3.7.0 to v3.7.1. The page continues to display a 403 error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-11T05:26:47.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    403 Forbidden error page is now shown, replacing the expected study record content. The page includes the standard header, navigation, and footer, indicating access is blocked rather than a new or edited study entry.
    Difference
    18%
    Check dated 2026-09-20T03:08:54.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    The study page shows an updated revision label from v3.6.5 to v3.6.6, indicating a small documentation update.
    Difference
    0.1%
    Check dated 2026-08-29T23:51:27.000Z thumbnail image

Stay in the know with updates to ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.